- Trial Phase
- Phase 2
- Time to Market
- Unknown — if Phase 2 data is positive, the company would need to advance to Phase 3 trials and ultimately file for FDA approval, a process typically taking 3-5+ years for a novel CNS drug.
- Why 7/10
- The next hard, dated catalyst is the Phase 2 CALMA trial topline readout for Alzheimer's agitation, expected in Q4 2026 (within ~2 months from late October 2026). This is the company's lead and virtually only pipeline asset, and IGC is a ~$27M micro-cap with no other significant revenue streams; a positive or negative readout will drive the stock massively. However, this is a Phase 2 (not pivotal Phase 3) readout, which limits the score to 7.
Watch for the Phase 2 CALMA trial topline results expected in Q4 2026 (within ~2 months) — this is the binary catalyst for IGC stock. A positive readout on Alzheimer's agitation could drive significant upside given the micro-cap valuation (~$27M) and analyst price targets near $6. However, the company has heavy cash burn, recurring dilutive financing, and the stock trades near its 52-week low, so any miss would be punishing. Consider position-sizing accordingly and be prepared for either outcome.
Price Chart
Executive Summary
IGC-AD1 is IGC Pharma's lead drug candidate, a low-dose THC-based formulation in Phase 2 development for agitation in Alzheimer's disease. The CALMA Phase 2 trial (NCT, 168 patients randomized) has completed enrollment, with final dosing expected in November 2026 and topline results due in Q4 2026. This is the defining catalyst for IGC, a micro-cap pharma trading at ~$0.246/share (~$27M market cap) with 4 Buy/Strong Buy analyst ratings and a $6 price target. However, the company faces significant headwinds: heavy cash burn ($4.1M net loss on $0.9M revenue over nine months), repeated dilutive financing at high interest rates, insider stock gifting, and institutional near-exits. The Phase 2 readout is a high-risk binary: success could be transformative; failure would likely devastate the stock.
How It Works
IGC-AD1 is a proprietary, low-dose formulation of tetrahydrocannabinol (THC), the psychoactive compound in cannabis, designed to treat agitation in Alzheimer's disease patients. It targets the brain's endocannabinoid system — specifically CB1 receptors — to modulate neurotransmitter release and calm overactive neural circuits that drive agitation and aggression. The low-dose design aims to provide the behavioral benefits of THC (anxiety reduction, sedation) while minimizing psychoactive side effects common at higher doses.
Trial Status
The Phase 2 CALMA trial for Alzheimer's agitation has completed enrollment of 168 randomized participants. Final dosing is expected in November 2026, with topline results anticipated in Q4 2026. The study is a randomized, double-blind, placebo-controlled trial evaluating IGC-AD1's efficacy and safety in treating agitation symptoms in Alzheimer's disease patients.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 CALMA trial topline results — Q4 2026 (the single most important catalyst)
- Final dosing of CALMA trial participants — November 2026
- IGC Q2 2027 earnings — November 18, 2026
- Annual shareholder meeting — December 2, 2026 (includes vote on increased share reserve and 5M compensation shares)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
IGC Pharma, Inc. DEF 14A IGC ·Originating report